会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • VACCINE
    • 疫苗
    • WO2004080375A2
    • 2004-09-23
    • PCT/EP2004/002643
    • 2004-03-11
    • GLAXOSMITHKLINE BIOLOGICALS S.A.MEYKENS, ReneMETTENS, PascalMONTEYNE, Philippe
    • MEYKENS, ReneMETTENS, PascalMONTEYNE, Philippe
    • A61K
    • A61K39/0012A61K38/00A61K39/00A61K2039/505C07K14/775C07K16/18
    • The present invention relates to novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases. Accordingly there is provided, immunogens comprising specific fragments or derivatives of Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, are potent in the prevention, or reduction, of atherosclerotic plaque formation over prolonged periods of time, thereby reducing the potential of atherosclerosis leading to coronary or cerebrovascular disease. Also provided are methods of treating or preventing atherosclerosis by active vaccination, or passive vaccination through administration to a patient of an antibody that is capable of binding to the specific fragments of ApoCIII. Specific monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the immunogens of the present invention in medicine, and methods of their production. The fragments of ApoCIII which form the basis of the immunogens of the present invention, and also the targets for passive immunotherapy, are encompassed within the regions between amino acid numbers 45-76 and, particularly, 12-35 of the mature form of human ApoCIII.
    • 本发明涉及新型疫苗疗法和动脉粥样硬化疾病的预防性治疗。 因此,提供了包含载脂蛋白C-III(ApoCIII)的特异性片段或衍生物的免疫原。 包含所述免疫原的本发明的疫苗在延长的时间段内有效预防或减少动脉粥样硬化斑块的形成,从而降低导致冠状动脉或脑血管疾病的动脉粥样硬化的可能性。 还提供了通过主动接种治疗或预​​防动脉粥样硬化的方法,或通过向患者施用能够结合到ApoCIII的特异性片段的抗体的被动接种。 提供特异性单克隆抗体及其在治疗动脉粥样硬化中的应用。 还提供了本发明的免疫原在医药中的用途及其制备方法。 形成本发明的免疫原的基础的ApoCIII的片段以及被动免疫治疗的靶标包含在成熟形式的人ApoCIII的氨基酸数45-76之间,特别是12-35的区域内 。
    • 9. 发明申请
    • VACCINE
    • 疫苗
    • WO2004081045A2
    • 2004-09-23
    • PCT/EP2004/002642
    • 2004-03-11
    • GLAXOSMITHKLINE BIOLOGICALS S.A.METTENS, PascalMONTEYNE, Philippe
    • METTENS, PascalMONTEYNE, Philippe
    • C07K14/775
    • C07K14/775A61K39/0012
    • The present invention relates to novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases. Accordingly there is provided, immunogens comprising specific fragments or derivatives of oxidised Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, are potent in the prevention, or reduction, of atherosclerotic plaque formation over prolonged periods of time, thereby reducing the potential of atherosclerosis leading to coronary or cerebrovascular disease. Also provided are methods of treating or preventing atherosclerosis by active vaccination, or passive vaccination through administration to a patient of an antibody that is capable of binding to the specific fragments of ApoCIII. Specific monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the immunogens of the present invention in medicine, and methods of their production. The fragments of ApoCIII which form the basis of the immunogens of the present invention, and also the targets for passive immunotherapy, are encompassed within the regions between amino acid numbers 45-76 and, particularly, 12-35 of the mature form of human ApoCIII.
    • 本发明涉及新型疫苗疗法和动脉粥样硬化疾病的预防性治疗。 因此,提供了包含氧化的载脂蛋白C-III(ApoCIII)的特异性片段或衍生物的免疫原。 包含所述免疫原的本发明的疫苗有效地预防或减少长时间的动脉粥样硬化斑块形成,从而降低导致冠状动脉或脑血管疾病的动脉粥样硬化的可能性。 还提供了通过主动接种治疗或预​​防动脉粥样硬化的方法,或通过向患者施用能够结合到ApoCIII的特异性片段的抗体的被动接种。 提供特异性单克隆抗体及其在治疗动脉粥样硬化中的应用。 还提供了本发明的免疫原在医药中的用途及其制备方法。 形成本发明免疫原的基础的ApoCIII片段以及被动免疫治疗的靶标包含在成熟形式的人ApoCIII的氨基酸数45-76之间,特别是12-35的区域内 。